for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Regeneron Pharmaceuticals Inc

REGN.OQ

Latest Trade

643.35USD

Change

-4.83(-0.75%)

Volume

208,473

Today's Range

639.78

 - 

660.09

52 Week Range

441.14

 - 

686.01

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
648.18
Open
660.00
Volume
208,473
3M AVG Volume
16.10
Today's High
660.09
Today's Low
639.78
52 Week High
686.01
52 Week Low
441.14
Shares Out (MIL)
107.54
Market Cap (MIL)
69,707.23
Forward P/E
9.16
Dividend (Yield %)
--

Next Event

Regeneron Pharmaceuticals Inc at Evercore ISI HealthCONx Virtual Conference

Latest Developments

More

EC Formally Authorises COVID-19 Drugs From Regeneron-Roche, Celltrion

EMA's CHMP Recommends Authorising Ronapreve And Regkirona For COVID-19

New Phase 3 Analyses Show That a Single Dose of REGEN-COV Provides Long-term Protection Against COVID-19

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company's commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. It is also engaged in the research, development of monoclonal antibodies, which consists of Dupixent, Kevzara, and itepekimab. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.

Industry

Biotechnology & Drugs

Contact Info

777 Old Saw Mill River Rd

TARRYTOWN, NY

10591-6717

United States

+1.914.8477000

https://www.regeneron.com/

Executive Leadership

P. Roy Vagelos

Chairman of the Board

Leonard S. Schleifer

President, Chief Executive Officer, Founder, Director

George D. Yancopoulos

President, Chief Scientific Officer, Director

Robert E. Landry

Chief Financial Officer, Executive Vice President - Finance

Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

Key Stats

2.11 mean rating - 27 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

6.7K

2019

7.9K

2020

8.5K

2021(E)

15.4K
EPS (USD)

2018

22.840

2019

24.670

2020

31.470

2021(E)

70.741
Price To Earnings (TTM)
10.35
Price To Sales (TTM)
5.15
Price To Book (MRQ)
4.08
Price To Cash Flow (TTM)
9.59
Total Debt To Equity (MRQ)
15.64
LT Debt To Equity (MRQ)
11.47
Return on Investment (TTM)
41.51
Return on Equity (TTM)
35.19

Latest News

Latest News

Factbox-Front runners in development of antibody drugs against COVID-19

AstraZeneca, Eli Lilly, Regeneron and GlaxoSmithKline are among the biggest pharmaceutical companies to have developed COVID-19 treatments using a class of drugs called monoclonal antibodies.

EU regulator backs COVID-19 drugs from Regeneron-Roche, Celltrion

Europe's drug regulator has recommended two COVID-19 antibody therapies - one from American-Swiss partners Regeneron-Roche and another from South Korea's Celltrion, as the region builds up its defence against surging cases.

Regeneron's antibody drug shows protection against COVID-19 for up to 8 months

Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in a late-stage trial, in the two to eight months period following the drug's administration.

Regeneron's antibody therapy shows long-term protection against COVID-19

Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period since the administration of the drug in a late-stage trial. (Reporting by Manojna Maddipatla in Bengaluru...

Regeneron beats quarterly sales on COVID-19 drug demand

Regeneron Pharmaceuticals Inc on Thursday reported higher-than-expected quarterly revenue on strong demand for its COVID-19 antibody cocktail during the Delta variant-led surge in infections in the United States.

Regeneron quarterly profit nearly doubles on strong demand for eczema drug

Regeneron Pharmaceuticals Inc's third-quarter profit nearly doubled on Thursday, helped by robust demand for its blockbuster drugs Dupixent to treat eczema and eye treatment Eylea.

EU assesses Regeneron/Roche COVID-19 antibody cocktail for authorisation

The European Union's drugs regulator said it was evaluating a marketing authorisation for an antibody cocktail developed by Roche and Regeneron for the treatment and prevention of COVID-19 in people above the age of 12.

Govt to control distribution of GSK/Vir COVID-19 antibody in U.S. - FDA

The U.S. Food and Drug Administration said on Friday distribution of GlaxoSmithKline and Vir Biotechnology's antibody treatment for COVID-19 would be controlled by the government.

WHO backs Regeneron COVID-19 drug cocktail as UN body calls for equal access

A World Health Organization (WHO) panel on Friday recommended the use of Regeneron and Roche's COVID-19 antibody cocktail for patients at high risk of hospitalisations and those severely ill with no natural antibodies.

U.S. buys additional doses of Eli Lilly, Regeneron COVID-19 therapy

Eli Lilly and Company said on Wednesday the U.S. government bought 388,000 additional doses of its COVID-19 antibody therapy, as infections surge due to the fast-spreading Delta variant.

U.S. to buy 1.4 million additional doses of Regeneron's COVID-19 therapy

Regeneron Pharmaceuticals Inc said on Tuesday the U.S. government will buy 1.4 million additional doses of its COVID-19 antibody cocktail, REGEN-COV.

U.S. to buy 1.4 mln additional doses of Regeneron's COVID-19 therapy

Regeneron Pharmaceuticals Inc said on Tuesday the U.S. government will buy 1.4 million additional doses of its COVID-19 antibody cocktail, REGEN-COV.

Pfizer study shows skin disease drug more effective than Regeneron rival

Pfizer Inc's experimental drug to treat patients with moderate-to-severe atopic dermatitis met the main goals of improving symptoms in adult patients compared to a rival treatment from Regeneron Pharmaceutical Inc.

UK approves Regeneron/Roche antibody cocktail for COVID-19

The UK drug regulator has approved an antibody cocktail developed by Regeneron and Roche to prevent and treat COVID-19, it said on Friday, as the nation battles rising hospitalisations due to the more infectious Delta variant.

UK regulator approves first monoclonal antibody treatment for COVID-19

The UK health regulator said on Friday it has approved Ronapreve, the antibody developed by Roche and Regeneron, to prevent and treat COVID-19.

Regeneron sees uptick in COVID-19 therapy use as cases rise

Regeneron Pharmaceuticals Inc on Thursday blew past analysts' estimates for second-quarter profit and revenue and said it has seen a recent uptick in the use of its COVID-19 therapy by patients in the United States.

Regeneron quarterly profit more than triples on COVID-19 antibody cocktail demand

Regeneron Pharmaceuticals Inc reported a more than tripling of its quarterly profit on Thursday, helped mainly by robust demand for its COVID-19 antibody cocktail.

FDA okays Regeneron COVID-19 antibody as preventive in high-risk settings

The U.S. Food and Drug Administration has expanded the emergency use authorization of Regeneron Pharmaceuticals Inc's COVID-19 antibody cocktail, enabling its use as a preventive treatment for the illness in certain people.

Regeneron antibodies help asymptomatic and hospitalized patients; some lymph node cancers limit vaccine response

The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

Bahrain approves emergency use for regn-cov2 medicine - BNA

Bahrain on Wednesday approved the emergency use for regn-cov2 medicine, Regeneron Pharmaceuticals Inc’s and Roche's newly authorized COVID-19 antibody combination, as part of its coronavirus treatment protocol to treat existing cases with mild and moderate symptoms, the...

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up